Table 3 |.

Market-approved cell therapies (excluding umbilical cord blood products)

Product	Drug name and application	Company
FDA approved
LAVIV	Azficel-T (autologous skin fibroblasts for aesthetic applications)	Fibrocell Technologies
MACI	Autologous cultured chondrocytes on a porcine collagen membrane	Vericel
GINTUIT	Allogeneic cultured keratinocytes and fibroblasts in bovine collagen	Organogenesis
IMLYGIC	Talimogene laherparepyec (oncolytic viral therapy)	BioVex (Amgen)
KYMRIAH	Tisagenlecleucel (CAR-T cancer therapy for B-cell tumours)	Novartis
LUXTURNA	Voretigene neparvovec-rzyl (adeno-associated virus vector gene therapy)	Spark Therapeutics
PROVENGE	Sipuleucel-T (autologous dendritic cell therapy for prostate cancer)	Dendreon
YESCARTA	Axicabtagepe ciloleucel (CAR-T cancer therapy for B-cell tumours)	Kite
EMA approved
HOLOCLAR	Ex vivo expanded autologous corneal epithelial cells for corneal burns	Holostem TA
STRIMVELIS	CD34+ cells transduced with ADA cDNA for severe combined immunodeficiency gene therapy	GlaxoSmithKline
ZALMOXIS	Allogeneic T cells transduced with nerve growth factor and HSV-TK Mut2 for graft-versus-host disease	MolMed SpA
CX601	Allogeneic adipose-derived ‘stem’ cells for perinatal fistulas and Crohn’s disease	Tigenix

ADA, adenosine deaminase; CAR, chimeric antigen receptor.